Protective function of p27KIP1 against apoptosis in small cell lung cancer cells in unfavorable microenvironments

被引:37
作者
Masuda, A
Osada, H
Yatabe, Y
Kozaki, K
Tatematsu, Y
Takahashi, T
Hida, T
Takahashi, T
Takahashi, T
机构
[1] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi 464, Japan
[4] Aichi Canc Ctr Hosp, Dept Pulm Med, Nagoya, Aichi 464, Japan
关键词
D O I
10.1016/S0002-9440(10)63947-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A previous study of ours unexpectedly found that in contrast to frequent reductions in non-small cell lung cancer, high expression of the p27(KIP1) cyclin-dependent kinase (CDK) inhibitor was retained in virtually all small cell lung cancers (SCLCs), suggesting the possibility of high expression of nonfunctional p27(KIP1) in this virulent tumor. The study presented here, however, shows that p27(KIP1) in SCLC biochemically functions as a CDK inhibitor, clearly showing induction apparently associated with G(1)/G(0) arrest and efficient binding to and inhibition of the cyclin E-CDK2 complex. Interestingly, induction of p27(KIP1) seems to confer on SCLC cells the ability to survive under culture conditions unfavorable for cell growth such as a lack of nutrients and hypoxia. Subsequent experiments manipulating p27(KIP1) levels by using a sense p27(KIP1) expression construct or an antisense oligonucleotide supported this notion. These observations suggest that high expression of p27(KIP1) in vivo may favor the survival of SCLC by preventing apoptosis in a microenvironment unfavorable for cell proliferation.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 27 条
[11]  
Minna John D., 1997, P849
[12]   DELETIONS OF THE CYCLIN-DEPENDENT KINASE-4 INHIBITOR GENE IN MULTIPLE HUMAN CANCERS [J].
NOBORI, T ;
MIURA, K ;
WU, DJ ;
LOIS, A ;
TAKABAYASHI, K ;
CARSON, DA .
NATURE, 1994, 368 (6473) :753-756
[13]   The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury [J].
Ophascharoensuk, V ;
Fero, ML ;
Hughes, J ;
Roberts, JM ;
Shankland, SJ .
NATURE MEDICINE, 1998, 4 (05) :575-580
[14]  
PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211
[15]   COMPLEX INTRACHROMOSOMAL REARRANGEMENT IN THE PROCESS OF AMPLIFICATION OF THE L-MYC GENE IN SMALL-CELL LUNG-CANCER [J].
SEKIDO, Y ;
TAKAHASHI, T ;
MAKELA, TP ;
OBATA, Y ;
UEDA, R ;
HIDA, T ;
HIBI, K ;
SHIMOKATA, K ;
ALITALO, K ;
TAKAHASHI, T .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (04) :1747-1754
[16]   Cancer cell cycles [J].
Sherr, CJ .
SCIENCE, 1996, 274 (5293) :1672-1677
[17]  
St Croix Brad, 1997, Current Opinion in Oncology, V9, P549
[18]  
StCroix B, 1996, NAT MED, V2, P1204
[19]   P53 - A FREQUENT TARGET FOR GENETIC ABNORMALITIES IN LUNG-CANCER [J].
TAKAHASHI, T ;
NAU, MM ;
CHIBA, I ;
BIRRER, MJ ;
ROSENBERG, RK ;
VINOCOUR, M ;
LEVITT, M ;
PASS, H ;
GAZDAR, AF ;
MINNA, JD .
SCIENCE, 1989, 246 (4929) :491-494
[20]  
TRAVIS WD, 1996, LUNG CANC PRINCIPLES, P361